Persei vivarium, a pioneer company in Digital Health and part of the Zelenza Group, a leading Spanish company in technological solutions and innovative services, advances its proposal in oncology with a novel comprehensive solution designed for clinical monitoring and improving the health outcomes of oncology patients. This platform responds to the growing challenges posed by the increase in the incidence of cancer, the increase in the use of health resources and the complexity of treatments for health systems.
The current landscape of cancer care faces increasing care pressure. According to the latest estimates from REDECAN, it is expected that 301,884 new cases of cancer will be diagnosed in Spain in 2026. Added to this figure is the increase in survival and the aging of the population, factors that trigger the need for personalized and constant monitoring of the patient outside the hospital. In this context, adherence to treatments, mainly oral ones, is a key challenge, with studies showing that up to 28% of patients present some type of lack of adherence, directly affecting the effectiveness of the therapy. To respond to this reality, the new platform facilitates closer and continuous monitoring of patients.
Digital platform with tracking tools
The new solution from Persei vivarium, from the Zelenza Group, directly addresses these challenges. It is a digital platform that combines patient monitoring tools, personalized educational programs and advanced clinical monitoring capabilities. This platform integrates different functionalities in a single digital environment. The objective is to optimize continuity of care, facilitate the early detection of toxicities and, ultimately, improve adherence to treatment and the patient’s quality of life.
“With this initiative, at Zelenza we put our 40 years of experience at the service of a key objective: transforming healthcare. We have combined our knowledge in critical technologies with the specialization of Persei vivarium to create an innovative, robust and scalable tool. This platform will tangibly improve care for cancer patients,” says José Fernández, President of Zelenza.
Roberto Bravo, CEO of Persei vivarium, added: “This tool materializes our vision of a more personalized and proactive care model, offering healthcare professionals more efficient follow-up and cancer patients the support they need during their pathology and treatment. The platform allows a more fluid interaction between patients and healthcare professionals. By being part of Zelenza and having access to the resources and capabilities they provide, we can take a step further in the development of innovative solutions that directly impact the quality and efficiency of the health care.”
The platform allows a more fluid interaction between patients and healthcare professionals
This comprehensive project is a firm step towards the future of health, a vision in which Digital Therapies and technological solutions are indispensable allies in patient care. The Persei vivarium platform, from the Zelenza Group, not only responds to a current challenge, but also opens the door to a new paradigm of personalized medicine. Furthermore, this platform is designed to evolve alongside the needs of the healthcare system, demonstrating how technology can transform the experience of cancer patients, improve their quality of life and enhance their well-being at each stage of treatment.
